13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-β-elemene, a novel β-elemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast cancer cells

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1554-1558

  Ding, Xiao Fei ^a   Shen, Mao ^a   Xu, Li Ying ^b   Dong, Jin Hua ^b   Chen, Guang ^a  

^a TAIZHOU UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

elemene; 13,14 bis(cis 3,5 dimethyl 1 piperazinyl) elemene; Autophagy; Cancer; MTOR

Indexed keywords

13, 14 BIS (CIS 3,5 DIMETHYL 1 PIPERAZINYL) BETA ELEMENE; BETA ELEMENE; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; DOXORUBICIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SCREENING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; SARCOMA 180; WESTERN BLOTTING;

EID: 84875759401     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1213     Document Type: Article

References (19)

1. World Health Organization: Programmes and projects: Cancer: Breast Cancer Awareness Month in October. http://www.who.int/cancer/events/breast_cancer_month/en/index.html. Accessed October 31, 2011.
2. National Cancer Institute: Cancer statistics: SEER stat fact sheets, breast. http://seer.cancer.gov/statfacts/html/breast.html. Accessed April 5, 2011
3. Guo YT: Isolation and identification of elemene from the essential oil of Curcuma wenyujin. Zhong Yao Tong Bao 8: 31, 1983 (In Chinese).
4. Tan P, Zhong W and Cai W: Clinical study on treatment of 40 cases of malignant brain tumor by elemene emulsion injection. Zhongguo Zhong Xi Yi Jie He Za Zhi 20: 645-648, 2000 (In Chinese).
5. Peng X, Zhao Y, Liang X, et al: Assessing the quality of RCTs on the effect of beta-elemene, one ingredient of a Chinese herb, against malignant tumors. Contemp Clin Trials 27: 70-82, 2006.
6. Tao L, Zhou L, Zheng L and Yao M: Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo. Cancer Chemother Pharmacol 58: 24-34, 2006.
7. Wang J, Zhang H and Sun Y: Phase III clinical trial of elemenum emulsion in the management of malignant pleural and peritoneal effusions. Zhonghua Zhong Liu Za Zhi 18: 464-467, 1996 (In Chinese).
8. Xu L, Tao S, Wang X, et al: The synthesis and anti-proliferative effects of beta-elemene derivatives with mTOR inhibition activity. Bioorg Med Chem 14: 5351-5356, 2006.
9. Carew JS, Kelly KR and Nawrocki ST: Autophagy as a target for cancer therapy: new developments. Cancer Manag Res 4: 357-365, 2012.
10. Liu J, Hu XJ, Jin B, Qu XJ, Hou KZ and Liu YP: β-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells. J Pharm Pharmacol 64: 146-153, 2012.
11. Butler MS: The role of natural product chemistry in drug discovery. J Nat Prod 67: 2141-2153, 2004.
12. Qing C, Zhang JS and Ding J: In vitro cytotoxicity of salvicine, a novel diterpenoid quinone. Zhongguo Yao Li Xue Bao 20: 297-302, 1999.
13. Kollmannsberger C, Mross K, Jakob A, Kanz L and BokemeyerC: Topotecan-A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56: 1-12, 1999.
14. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
15. Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318, 2009.
16. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
17. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
18. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
19. Wan X and Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 12: 1007-1018, 2007.